NCT05604131

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 89 (estimated)
• Sponsor: Rohan Dharmakumar · Academic / Other
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.

Conditions

• Acute Myocardial Infarction Type 1

Interventions

Type	Name	Description
DRUG	Deferiprone Tablets	Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
DRUG	Placebo	Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.

Timeline

• Start date: 2022-11-08
• Primary completion: 2029-03-31
• Completion: 2029-08-31
• First posted: 2022-11-03
• Last updated: 2026-04-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study